Answers are grounded in this paper and cite their sources.
Despite substantial advances in targeted therapeutic regimens for breast cancer (BC), clinical management remains challenging for refractory and therapy-resistant cases, especially for molecular subtypes lacking validated actionable targets. Here, we identified that FK506-binding protein 10 (FKBP10), a peptidyl-proline isomerases, was strikingly elevated in BC tissues and potentiated the malignant behaviors of BC cells in vitro and in vivo. Besides, we discovered that FKBP10 was positively correlated with enhanced homologous recombination (HR)-mediated DNA repair and drove broad resistance to multiple DNA-damaging therapies, including cisplatin, ionizing radiation (IR) and PARP inhibitor. Mechanistically, FKBP10 physically interacted with the core HR repair protein RAD51 via a proline 22-containing motif. This interaction competitively disrupted the recognition of RAD51 by heat shock cognate 70 (HSC70), thereby protecting RAD51 from chaperone-mediated autophagy (CMA)-dependent degradation. Furthermore, FKBP10 attenuated excessive CMA flux to further stabilize RAD51 in the manner of ATF6-mediated endoplasmic reticulum stress (ERS). Importantly, we characterized a clinically actionable repurposing strategy using selumetinib, which transcriptionally repressed FKBP10 by blocking the MEK/ERK/ELK1 signaling cascade. This pharmacological intervention robustly sensitized multiple preclinical BC models to chemoradiotherapy and PARP inhibition. Collectively, our findings uncover a previously unappreciated function of FKBP10 in driving BC progression and resistance to DNA-damaging therapies, underscoring its strong potential as a tractable therapeutic target for treatment-refractory BC subsets.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: